The Period PROUD Act directs dedicated federal funding through the Social Services Block Grant (title XX) framework to expand free menstrual-product distribution to people with limited access. It authorizes a discrete pool of funds, defines eligible recipients, limits administrative costs, and requires an HHS evaluation of program outcomes.
This is a targeted, programmatic intervention: rather than creating a new entitlement or universal benefit, the bill channels resources to states, tribes, local governments, and qualified nonprofits to purchase and distribute menstrual cups, discs, underwear, pads, and tampons and to integrate distribution with existing basic-needs programs.
At a Glance
What It Does
The bill designates a portion of title XX Social Services Block Grant resources and appropriates additional funds to finance the distribution of menstrual products, establish eligibility criteria for grantees, and set rules for allowable uses, reporting, and an HHS-led evaluation.
Who It Affects
State title XX administrators, local governments, Indian tribes, 501(c)(3) nonprofits experienced in basic-needs distribution, community health programs, shelters, schools, and supply-chain partners who provide menstrual products.
Why It Matters
It creates a federal funding stream focused specifically on menstrual-product access, establishes federal guardrails (reporting, evaluation, admin cap), and integrates product distribution into existing social‑service delivery systems — potentially reshaping how basic‑needs programs address menstrual health needs.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill works inside the existing title XX Social Services Block Grant (SSBG) structure. It sets aside a defined set of federal dollars to be distributed by states to eligible entities — which include state and local governments, Indian tribes, and nonprofits with distribution experience — for purchasing and distributing menstrual products and for related outreach and training.
HHS (the Secretary) must issue guidance within 180 days explaining eligibility, allowable uses, and reporting.
Funding is structured two ways: the bill specifies a deemed SSBG amount for fiscal years 2025–2028 and separately appropriates money from the Treasury for fiscal years 2026–2029. HHS may reserve a small percentage of the appropriated funds for technical assistance and up to $2 million in the first appropriation year for an evaluation.
States must distribute the funds to eligible entities, and grantees may use them to buy and distribute menstrual products, integrate distribution with other basic-needs programs, provide technical assistance, and cover administrative costs — but administrative spending is capped at 9 percent.The bill also builds in oversight: payments to states under this section are subject to title XX reporting rules; the Secretary must complete an evaluation of program effectiveness by December 30, 2031, and publish and deliver the results to relevant congressional committees in early 2032. The statute prohibits restricting where products may be distributed, requires funds to supplement — not replace — existing federal, state, local, or philanthropic funding, and exempts these appropriations from sequestration.
The Five Things You Need to Know
The bill sets a specific title XX funding framework: for fiscal years 2025–2028 the SSBG amount is deemed $1.9 billion and directs that $200 million (less reserved amounts) be obligated by States annually for menstrual‑product activities.
Congress appropriates $200 million per year for fiscal years 2026–2029 to carry out the program, and HHS may reserve up to 2% of those appropriated funds each year for technical assistance, plus up to $2 million in fiscal year 2026 for the program evaluation.
Eligible recipients include States, local governments, Indian tribes, and 501(c)(3) nonprofits with experience collecting, warehousing, and distributing basic-need items; nonprofits must demonstrate fiscal competence and a willingness to share information with researchers.
An eligible grantee may spend program funds to purchase and distribute menstrual products, integrate distribution with other assistance programs (TANF, Medicaid/CHIP, WIC, home visiting), provide training/TA, and cover administrative costs — but may not use more than 9% of funds for administration.
HHS must evaluate program effectiveness (completion by December 30, 2031), report results to congressional committees by March 31, 2032, publish findings by April 30, 2032, and issue implementation guidance within 180 days of enactment.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
States the Act’s public name: the Period PROUD (Providing Resources for Our Underserved and Disadvantaged) Act of 2025. This is purely stylistic but important for cross-references and appropriation language.
Designates SSBG funding and creates an appropriation stream
The bill ‘deems’ the title XX funding level at $1.9 billion for FY2025–FY2028 and directs that $200 million (adjusted for reserves) be obligated by States for menstrual product activities each of those years. Separately, it appropriates $200 million per year from the Treasury for FY2026–FY2029 to be used for the program. Practically, that dual structure (a deemed SSBG level plus separate appropriations) creates a predictable pool earmarked for menstrual-product distribution while using the existing SSBG administrative and allocation machinery.
HHS reservations: technical assistance and evaluation dollars
HHS may reserve up to 2% of the appropriated funds for entering agreements with qualified nonprofit partners to provide technical assistance, training, and cross‑system collaboration support for grantees. In addition, up to $2 million is available in FY2026 for the evaluation. The statute also specifies that states do not have an entitlement to these reserved funds — HHS controls the reservation and selection process.
What grantees may spend money on and constraints
States must distribute funds to eligible entities after stakeholder consultation. Grantees may buy and distribute menstrual products, integrate distribution into TANF, Medicaid/CHIP, WIC, and home‑visiting programs, provide training/TA, and cover administrative costs (capped at 9%). The funds must supplement, not supplant, other federal, state, local, or philanthropic resources, and distribution locations cannot be restricted by the Secretary.
Reporting obligations, evaluation schedule, and HHS guidance
Payments under this authority are subject to title XX reporting rules (section 2004), and HHS must complete an evaluation by December 30, 2031, report to specified congressional committees by March 31, 2032, and publish results online by April 30, 2032. The Secretary must issue implementation guidance within 180 days of enactment covering eligibility, allowable uses, and reporting.
Key definitions and fiscal/administrative provisions
The statute defines ‘menstrual products’ to include cups, discs, underwear, pads, and tampons that meet industry standards; defines eligible entities (States, local governments, tribes, and qualified 501(c)(3)s); caps HHS administrative authorization at $6 million for FY2026–FY2029; and makes the funds exempt from sequestration under the Balanced Budget and Emergency Deficit Control Act.
This bill is one of many.
Codify tracks hundreds of bills on Social Services across all five countries.
Explore Social Services in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Low‑income menstruating individuals served by shelters, schools, community health centers and other community distribution sites — they gain free access to a broader range of menstrual products, potentially reducing unmet needs and associated health/hygiene risks.
- Community 501(c)(3) distribution organizations (food banks, diaper banks, mutual‑aid groups) that already collect and distribute basic necessities — the bill funds scale‑up, storage, and logistics and funds technical assistance to strengthen their operations.
- Tribal governments and urban Indian health programs — the statute expressly includes tribes as eligible entities, creating a channel for targeted tribal distributions and culturally appropriate outreach.
- State and local social‑service systems — program integration options let states embed menstrual‑product distribution in TANF, WIC, Medicaid/CHIP, and home‑visiting services, improving coordination and reach.
Who Bears the Cost
- Federal Treasury — the bill appropriates $200 million per year for FY2026–FY2029 and authorizes up to $6 million for program administration; these are direct fiscal costs to federal appropriations.
- State title XX administrators — states must obligate funds, distribute to subgrantees, comply with reporting, and ensure non‑supplanting, which creates administrative burdens and potential fiscal tracking requirements.
- Nonprofit grantees and local programs — while eligible for purchase funds, they must meet competency, fiscal‑accountability, and reporting requirements; the 9% cap on admin costs may squeeze smaller organizations with high overhead relative to program size.
- HHS and evaluation partners — HHS must develop guidance, run reservations for TA, oversee reporting, and complete a formal evaluation, requiring agency staff time and contractor resources.
Key Issues
The Core Tension
The central dilemma is between targeted, accountable federal support and the need for local flexibility: the bill aims to deliver measurable, federally overseen results (evaluation, reporting, reserved TA) while also allowing states and local partners broad discretion over distribution sites and integration with other programs — but stronger federal controls improve accountability and comparability across jurisdictions while tighter local flexibility improves responsiveness to local needs, and the bill attempts to do both without fully resolving how to reconcile them.
The bill balances targeted flexibility with federal oversight, but that balance creates operational ambiguities. ‘Supplement, not supplant’ language is standard but can be hard to enforce in practice: states and grantees will need clear accounting rules to show that funds expand access rather than replace existing spending. Similarly, integrating distribution into TANF, Medicaid/CHIP, WIC, and home‑visiting programs offers efficiency gains but raises cross‑program compliance questions (data sharing, eligibility alignment, and differing reporting cycles).
Measurement and evaluation pose practical challenges. The required evaluation aims to assess health risks mitigated by increased product access, but establishing causal links between product distribution and health outcomes requires baseline data, control groups, and consistent outcome metrics — none of which the bill prescribes in detail.
Small nonprofits may struggle under the 9% admin cap, which constrains investments in inventory management, data collection, and delivery logistics that are critical to effective distribution. Finally, the dual funding construct (a deemed SSBG level plus separate appropriations) may complicate state accounting and allocation formulas under existing title XX mechanisms.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.